Last reviewed · How we verify
NCT02783651
An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
trial testing Other in Relapsed/Refractory Acute Lymphoblastic Leukemia in 212 participants. Completed in 31 March 2020.
31 March 2020
Quick facts
| Lead sponsor | Amgen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 212 |
| Start date | 30 June 2016 |
| Primary completion | 31 March 2020 |
| Estimated completion | 31 March 2020 |
| Sites | 19 locations across United States |
Drugs / interventions tested
- Other
Conditions studied
- Relapsed/Refractory Acute Lymphoblastic Leukemia — all drugs for Relapsed/Refractory Acute Lymphoblastic Leukemia →
Sponsor
Amgen — full company profile →
Who can join
Eligibility, any sex, with Relapsed/Refractory Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A retrospective chart review study of Philadelphia chromosome-negative R/R ALL patients in the US.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review).
Queudeville M, Ebinger M. · · 2021 · cited 43× · PMID 34201368 · DOI 10.3390/jcm10122544
Verify or expand the search:
- PubMed search for NCT02783651
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Other
Trials testing the same drug.
- NCT07118163 — The Relationship Pain Beliefs With Kinesiophobia, Catastrophizing, Pain Knowledge, and Shoulder Functional Disability in · not yet recruiting
- NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
- NCT06802237 — Development and Standardization Methods · completed
- NCT06344611 — Incidence & Predictive Factors of Recompensation in Children With Decompensated Cirrhosis as Per the Baveno VII Criteria · unknown
- NCT06091475 — Therapy to Maintain Remission in Dilated Cardiomyopathy · NA · recruiting
Other Amgen trials
Trials by the same sponsor.
- NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
- NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
- NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
- NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
- NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02783651 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amgen
- Last refreshed: 27 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02783651.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing